A
Accera
Biotech & Life Sciences · Denver, United States · Founded 2001
Biotechnology company engaged in the discovery and development of therapeutic drugs for neurodegenerative diseases MoreLess
Accera Pharma, accessible via accerapharma.com, is a dynamic startup focused on developing innovative solutions for brain health. The company operates in the pharmaceutical and biotechnology market, targeting a global audience that includes patients, healthcare providers, and research institutions. Accera Pharma specializes in creating treatments for neurological conditions, aiming to improve the quality of life for individuals suffering from brain-related health issues.
The business model of Accera Pharma revolves around extensive research and development (R&D) to create proprietary drugs and therapies. The company invests heavily in clinical trials and regulatory approvals to ensure the safety and efficacy of its products. By doing so, Accera Pharma aims to bring groundbreaking treatments to market, addressing unmet medical needs in the field of neurology.
Accera Pharma generates revenue through the commercialization of its developed drugs. This includes direct sales to healthcare providers and partnerships with larger pharmaceutical companies for distribution. Additionally, the company may engage in licensing agreements, allowing other firms to market its products in exchange for royalties. This diversified approach helps Accera Pharma to maximize its market reach and financial stability.
The company serves a wide range of clients, including patients with neurological conditions, healthcare professionals seeking advanced treatment options, and research institutions interested in collaborative projects. By focusing on brain health, Accera Pharma positions itself in a niche yet critical segment of the healthcare industry, where there is a growing demand for innovative solutions.
In summary, Accera Pharma is a forward-thinking biotech startup dedicated to advancing brain health through innovative drug development. The company operates in the pharmaceutical and biotechnology market, serving patients, healthcare providers, and research institutions. Its business model is centered on R&D, clinical trials, and strategic partnerships, generating revenue through product sales and licensing agreements.
Keywords: Brain health, Neurological treatments, Pharmaceutical, Biotechnology, Drug development, Clinical trials, Healthcare, Innovation, Research, Licensing.
Company overview
Accera company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2001
- Headquarters
- Denver, United States
- Employees
- 37
- Open positions
- None listed
- Dealroom signal
- 36.0
- Investment activity
- 1 companies · latest Aug 2017
- Capital deployed
- —
- Preferred round
- ACQUISITION
Valuation & funding
Accera funding history
Company financing events and reported valuations.
Growth signals
Accera website traffic
Latest recorded traffic for Accera is 0 monthly website visits. Accera's team grew 0% over the past year.
Comparisons
Accera compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Accera investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Accera's talent
Source: Dealroom Talent Intelligence.
Investors
4 investors on Accera's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Accera has talent and traffic
In the news
Latest news about Accera
Recent press, funding announcements, and product moves mentioning Accera — open to read from the original sources.
Market sentiment
What the market is saying about Accera
An AI-synthesized read of the highest-engagement posts about Accera on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Accera’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.